Related Experiment Videos
Controversies of treatment modalities for cerebral venous thrombosis
Maria Khan1, Ayeesha Kamran Kamal, Mohammad Wasay
1Department of Medicine (Neurology), Aga Khan University, Stadium Road, Karachi 74800, Pakistan.
Insights
Cerebral venous thrombosis (CVT) treatments are limited by few trials. Anticoagulation with heparin is the only recommended therapy, while other methods are for select severe cases.
Area of Science:
- Neurology
- Vascular Medicine
Background:
- Cerebral venous thrombosis (CVT) is a recognized neurological condition.
- Therapeutic options for CVT are limited due to a scarcity of large randomized trials.
Purpose of the Study:
- To review the current therapeutic modalities for cerebral venous thrombosis.
- To assess the evidence supporting various treatment options for CVT.
Main Methods:
- Review of reported therapeutic modalities for CVT, including antiplatelets, anticoagulation, fibrinolysis, and mechanical thrombectomy.
- Analysis of existing literature, noting the limited number of randomized controlled trials.
Main Results:
- Anticoagulation, particularly with heparin, is the most widely used and evidence-supported treatment for CVT, backed by two randomized controlled trials.
- Antiplatelet agents are least studied, with only anecdotal evidence.
- Fibrinolysis (local infusions preferred over systemic) and mechanical thrombectomy show promise but lack robust evidence.
- Decompression surgery may be life-saving in malignant CVT with impending herniation.
Conclusions:
- Larger randomized controlled trials are essential to establish definitive therapeutics for CVT.
- Heparin anticoagulation is the primary evidence-based treatment for CVT.
- Endovascular thrombolysis, mechanical thrombectomy, and decompression surgery are reserved for refractory or severe cases of CVT.
Abstract:
Cerebral vein thrombosis has been well recognized for nearly two centuries. However, therapeutic options for the condition are limited due to lack of large randomized trials. The various modalities reportedly used include antiplatelets, anticoagulation, fibrinolysis, and mechanical thrombectomy. Of these, antiplatelets are the least studied, and there are only anecdotal reports of aspirin use. Anticoagulation is the most widely used and accepted modality with favorable outcomes documented in two randomized controlled trials. Various fibrinolytic agents have also been tried. Local infusions have shown more promise compared to systemic agents. Similarly, mechanical thrombectomy has been used to augment the effects of chemical thrombolysis. However, in the absence of randomized controlled trials; there is no concrete evidence of the safety and efficacy of either of these modalities. Limited study series disclosed that decompression surgery in malignant CVT can be life saving and provides good neurological outcome in some cases. Conclusion. Overall therapeutics for CVT need larger randomized controlled trials. Anticoagulaion with heparin is the only modality with a reasonable evidence to support its use in CVT. Endovascular thrombolysis and mechanical thrombectomy are reserved for selected cases who fail anticoagulation and decompression surgery for malignant CVT with impending herniation.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care